What happened
FDA’s Compounding Quality Center of Excellence describes two discussion series for outsourcing facilities to share issues, practices and solutions intended to improve compounded drug quality. The New Outsourcing Facility Discussion Series is aimed at newly registered facilities and includes an “Automation Basics” session on November 18, covering automation types, potential efficiency and quality benefits, and implementation challenges. The Quality Discussion Series focuses on quality culture, best practices and current good manufacturing practice requirements. Its January 12, 2027 session addresses integrating automated systems for quality outcomes, including change management, quality considerations and maintaining CGMP requirements while pursuing efficiencies. The page is current as of October 21, 2026.
Why it matters
For pharmaceutical manufacturing, the update may matter because it highlights automation as both an efficiency opportunity and a quality-system consideration for outsourcing facilities. FDA frames implementation around potential benefits, challenges, change management and continued maintenance of CGMP requirements. Participation may therefore help facility management and staff compare industry practices and consider how automated systems could support more robust quality systems and improved compounded drug quality.
Key topics: Automation basics for newly registered outsourcing facilities, Integrating automation for quality outcomes, Quality culture and CGMP practices in drug compounding